Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2019, Article ID 2864384, 6 pages
https://doi.org/10.1155/2019/2864384
Review Article

Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis

1Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2Second Department of Oncology, The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830001, China

Correspondence should be addressed to Da Li; nc.ude.ujz@wenocnoadil

Received 3 February 2019; Accepted 22 May 2019; Published 23 June 2019

Academic Editor: Vickram Ramkumar

Copyright © 2019 Jing Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Fearon, F. Strasser, S. D. Anker et al., “Definition and classification of cancer cachexia: an international consensus,” The Lancet Oncology, vol. 12, no. 5, pp. 489–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Argilés, S. Busquets, B. Stemmler, and F. J. López-Soriano, “Cancer cachexia: understanding the molecular basis,” Nature Reviews Cancer, vol. 14, no. 11, pp. 754–762, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Cohen, J. A. Nathan, and A. L. Goldberg, “Muscle wasting in disease: molecular mechanisms and promising therapies,” Nature Reviews Drug Discovery, vol. 14, no. 1, pp. 58–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. M. K. Barton, “Cancer cachexia awareness, diagnosis, and treatment are lacking among oncology providers,” CA: A Cancer Journal for Clinicians, vol. 67, no. 2, pp. 91-92, 2017. View at Publisher · View at Google Scholar
  5. E. Tazi and H. Errihani, “Treatment of cachexia in oncology,” Indian Journal of Palliative Care, vol. 16, no. 3, pp. 129–137, 2010. View at Publisher · View at Google Scholar
  6. J. P. Simons, A. M. Schols, J. M. Hoefnagels, K. R. Westerterp, G. P. Velde, and E. F. Wouters, “Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer,” Cancer, vol. 82, no. 3, pp. 553–560, 1998. View at Publisher · View at Google Scholar
  7. M. Zutt, H. Hänßle, S. Emmert, C. Neumann, and L. Kretschmer, “Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases,” Der Hautarzt, vol. 57, no. 5, pp. 423–427, 2006. View at Publisher · View at Google Scholar
  8. R. M. Langford, J. Mares, A. Novotna et al., “A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis,” Journal of Neurology, vol. 260, no. 4, pp. 984–997, 2013. View at Publisher · View at Google Scholar
  9. G. Bedi, R. W. Foltin, E. W. Gunderson et al., “Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study,” Psychopharmacology, vol. 212, no. 4, pp. 675–686, 2010. View at Publisher · View at Google Scholar
  10. A. Andries, J. Frystyk, A. Flyvbjerg, and R. K. Støving, “Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: results from a randomised, controlled trial,” Growth Hormone & IGF Research, vol. 25, no. 5, pp. 247–252, 2015. View at Publisher · View at Google Scholar
  11. J. C. Sipe, T. M. Scott, S. Murray et al., “Biomarkers of endocannabinoid system activation in severe obesity,” PLoS ONE, vol. 5, no. 1, Article ID e8792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. A. Jadoon, S. H. Ratcliffe, D. A. Barrett et al., “Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study,” Diabetes Care, vol. 39, no. 10, pp. 1777–1786, 2016. View at Publisher · View at Google Scholar
  13. S. von Haehling, M. Lainscak, J. Springer, and S. D. Anker, “Cardiac cachexia: a systematic overview,” Pharmacology & Therapeutics, vol. 121, no. 3, pp. 227–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. R. Johnson, M. Burnell-Nugent, D. Lossignol, E. D. Ganae-Motan, R. Potts, and M. T. Fallon, “Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain,” Journal of Pain and Symptom Management, vol. 39, no. 2, pp. 167–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Strasser, D. Luftner, K. Possinger et al., “Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the cannabis-in-cachexia-study-group,” Journal of Clinical Oncology, vol. 24, no. 21, pp. 3394–3400, 2006. View at Publisher · View at Google Scholar
  16. T. D. Brisbois, I. H. de Kock, S. M. Watanabe et al., “Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial,” Annals of Oncology, vol. 22, no. 9, pp. 2086–2093, 2011. View at Publisher · View at Google Scholar
  17. J. E. Beal, R. Olson, L. Laubenstein et al., “Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS,” Journal of Pain and Symptom Management, vol. 10, no. 2, pp. 89–97, 1995. View at Publisher · View at Google Scholar